Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Expected to Announce Earnings of -$0.91 Per Share
Wall Street analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to announce ($0.91) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aclaris Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.97) and the highest estimate coming in at ($0.81). Aclaris Therapeutics reported earnings per share of ($0.50) during the same quarter last year, which indicates a negative year-over-year growth rate of 82%. The company is scheduled to report its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Aclaris Therapeutics will report full year earnings of ($3.21) per share for the current year, with EPS estimates ranging from ($3.36) to ($2.97). For the next financial year, analysts expect that the firm will report earnings of ($3.46) per share, with EPS estimates ranging from ($3.64) to ($3.30). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.12.
A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Wednesday. BidaskClub lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Jefferies Group LLC reissued a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a report on Monday, July 31st. Guggenheim reissued a “buy” rating and set a $40.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Finally, ValuEngine raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $39.00.
Aclaris Therapeutics (NASDAQ:ACRS) traded down 13.05% during trading on Thursday, hitting $23.45. The stock had a trading volume of 202,179 shares. The firm has a 50 day moving average of $27.89 and a 200-day moving average of $27.99. The stock’s market cap is $626.96 million. Aclaris Therapeutics has a 12 month low of $18.24 and a 12 month high of $33.25.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. increased its position in Aclaris Therapeutics by 109.7% in the second quarter. Alliancebernstein L.P. now owns 19,500 shares of the biotechnology company’s stock worth $529,000 after buying an additional 10,200 shares in the last quarter. Wells Fargo & Company MN increased its position in Aclaris Therapeutics by 230.8% in the second quarter. Wells Fargo & Company MN now owns 40,883 shares of the biotechnology company’s stock worth $1,109,000 after buying an additional 28,524 shares in the last quarter. Franklin Resources Inc. increased its position in Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after buying an additional 697,104 shares in the last quarter. Kennedy Capital Management Inc. acquired a new position in Aclaris Therapeutics during the second quarter worth about $2,033,000. Finally, Rosenblum Silverman Sutton S F Inc. CA increased its position in Aclaris Therapeutics by 17.3% in the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after buying an additional 5,650 shares in the last quarter. Institutional investors own 88.64% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.